WO2019139307A1 - Composition pour le soin de la peau comprenant de la floculine - Google Patents

Composition pour le soin de la peau comprenant de la floculine Download PDF

Info

Publication number
WO2019139307A1
WO2019139307A1 PCT/KR2019/000184 KR2019000184W WO2019139307A1 WO 2019139307 A1 WO2019139307 A1 WO 2019139307A1 KR 2019000184 W KR2019000184 W KR 2019000184W WO 2019139307 A1 WO2019139307 A1 WO 2019139307A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
composition
saccharomyces
flocculin
usa
Prior art date
Application number
PCT/KR2019/000184
Other languages
English (en)
Korean (ko)
Inventor
유정진
김민지
김하영
강승현
김연준
박명삼
Original Assignee
코스맥스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스맥스 주식회사 filed Critical 코스맥스 주식회사
Priority to CN201980000340.5A priority Critical patent/CN110267643B/zh
Publication of WO2019139307A1 publication Critical patent/WO2019139307A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat

Definitions

  • composition for skin care To a composition for skin care.
  • Flocculin is a lectin-like protein in the Lager yeast cell wall, which serves to precipitate lager yeast.
  • it has a strong binding property with mannose, binds with mannose of other yeast walls, produces precipitates of yeast cells, and also has a function of protecting yeast from stress factors such as nutrient depletion, temperature and UV in the culture.
  • yeast is used as a cosmetic ingredient for the purpose of skin improvement such as wrinkle improvement and whitening effect.
  • the yeast extract is used as a cosmetic ingredient by removing yeast cells from the cell wall by proteolytic enzymes, organic solvents or autolysis, and then removing the insoluble portions and concentrating them.
  • the thus-treated yeast extract is composed of a complex of various proteins, peptides, amino acids, minerals and vitamin B groups and is useful as a cosmetic additive.
  • Other yeast extracts are known in skin wound healing and collagen synthesis effects (US Patent 5,776,441, US Patent 6,177,105) and are used as cosmetic raw materials. However, to date, there has been no use of flocurin in cosmetic compositions for skin care purposes.
  • One aspect provides a cosmetic composition for skin care comprising floculline.
  • Another aspect provides a composition for a health functional food for skin cosmetics comprising flocurin.
  • Another aspect provides a pharmaceutical composition for the cosmetic of the skin comprising flocucrin.
  • Another aspect provides a method of treating or ameliorating skin damage or aging comprising administering to an individual an effective amount of a composition comprising flocurin.
  • Another aspect provides the use of a composition comprising flocurin for the manufacture of a skin damaging or aging therapeutic agent.
  • One aspect provides a cosmetic composition for skin care comprising floculline. Another aspect provides a composition for a health functional food for skin cosmetics comprising flocurin. Another aspect provides a pharmaceutical composition for preventing or treating skin damage, or skin aging, comprising flocurin. Another aspect provides a composition for external application for skin cosmetics.
  • Flocculin generally refers to the lectin-like protein in the cell wall that is expressed in microorganisms of the genus Saccharomyces. Marika H. (1994) Purification and partial characterization of a flocculin from brewer's yeast ), Or can be obtained commercially by isolating it from microorganisms of the genus Saccharomyces according to a known method.
  • the composition may further comprise a culture or an extract of the microorganism of the genus Saccharomyces.
  • cultures or extracts can be readily obtained by a person skilled in the art according to methods known in the art.
  • culture of microorganisms can be carried out in a commercially available medium such as LB medium, Ham's F10 (Sigma), MEM (Minimal Essential Medium, Sigma), RPMI-1640 (Sigma), and DMEM (Dulbecco's Modified Eagle's Medium, Sigma) Etc. may be used.
  • LB medium such as Ham's F10 (Sigma), MEM (Minimal Essential Medium, Sigma), RPMI-1640 (Sigma), and DMEM (Dulbecco's Modified Eagle's Medium, Sigma) Etc.
  • hormones or other growth factors, salts, buffers, nucleotides, antibiotics, trace elements and glucose may be supplemented with known concentrations of known agents.
  • the culture conditions for example, temperature, pH and the like, can be appropriately determined by those skilled in the art depending on the selected microorganism.
  • the extract may be extracted with water, acetone, alcohol, for example, C1-C6 alcohol, or a mixture thereof as a solvent.
  • the C1-C6 alcohol may be methanol, ethanol, propanol, isopropanol, 1,3-propanediol, butanol, pentanol, or hexanol.
  • the solvent may be, for example, a mixture of water and an alcohol, that is, an aqueous solution of an alcohol.
  • the alcohol concentration of the alcohol aqueous solution may be 1 to 100 (v / v)%, for example, 1 to 99.5 (v / v)%, 10 to 100 (v / (V / v)%, 40 to 100 (v / v)%, 50 to 100 (v / v)%, 60 to 100 (v / (V / v)%, 60 to 90 (v / v)%, 60 to 80 (v / v)%, 65 to 75 have.
  • the aqueous alcohol solution may be methanol, ethanol, or an aqueous butanol solution.
  • the composition may further comprise a fraction of the extract.
  • fraction refers to a substance, i.e., a fractioned substance, in which the extract is divided into its components.
  • the fraction may be obtained by solvent fractionation.
  • the solvent fractionation may refer to mixing the extract with a solvent and separating the substance present in the solvent.
  • skin aesthetics refers to returning a skin damaged by skin damage or aging of the skin to a condition prior to damage, such as by wrinkles, volume enhancement, elasticity improvement, or skin regeneration.
  • the skin includes all parts of the body including the face, hands, arms, legs, feet, chest, belly, back, buttocks, and scalp.
  • skin damage refers to the damage caused by external physical damage, penetration of chemicals, bacteria, fungi, viruses, exposure to ultraviolet rays, skin moisture loss, wrinkles due to aging, oxidation by free radicals And include damage from a clinical and cosmetic point of view of skin tissue or cells, including skin, skin inflammation, seborrheic dermatitis, redness (erythema, erythema), edema, psoriasis, eczema, pruritus (itching), and atopic dermatitis .
  • the term "skin aging” includes endogenous aging with time and extrinsic aging by external environment.
  • the aging of the skin may include skin wrinkles, dullness, stain and the like.
  • the wrinkles of the skin may be reduced due to the degeneration of the skin.
  • Skin wrinkles can be due to photoaging, age, facial expression, lack of moisture, or a combination thereof.
  • the photoaging may be skin aging by exposure to ultraviolet light (including UVA, UVB, and UVC).
  • the skin wrinkle improvement may inhibit or inhibit the generation of wrinkles on the skin, or may alleviate the wrinkles already generated.
  • the composition may be formulated into a parenteral dosage form.
  • the parenteral dosage form may be an injection or an external preparation for skin.
  • the external preparation for skin may be a cream, a gel, an ointment, a skin emulsifier, a skin suspension, a transdermal patch, a drug-containing bandage, a lotion, or a combination thereof.
  • the external preparation for skin is usually used as a component used in external skin preparations such as cosmetics or medicines such as an aqueous component, an oily component, a powder component, an alcohol, a moisturizer, a thickener, an ultraviolet absorber, a whitening agent, an antiseptic, , Coloring agents, various skin nutrients, or a combination thereof, and may be suitably blended as necessary.
  • the external preparation for skin may be a metal blocker such as sodium edetate, sodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate or gluconic acid, caffeine, tannin, bellapamil, licorice extract, glabridine, Vitamin C, ascorbic acid magnesium phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, fructose, fructose and other herbal medicines, various herbal medicines, tocopherol acetate, glycyrrhizic acid, Saccharides such as trehalose can also be appropriately compounded.
  • a metal blocker such as sodium edetate, sodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate or gluconic acid, caffeine, tannin, bellapamil, licorice extract, glabridine, Vitamin C, ascorbic acid magnesium phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose
  • the cosmetic composition may be a cosmetic composition (skin lotion), a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrition lotion, a massage cream,
  • the composition may be formulated into a formulation comprising an active ingredient, an essence, a nutritional essence, a pack, a soap, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion, a body cleanser, a suspension, a gel, a powder, a paste, .
  • Compositions of such formulations may be prepared according to methods conventional in the art.
  • the cosmetic composition may contain at least one selected from the group consisting of preservatives, stabilizers, surfactants, thickeners, solubilizers, moisturizers, emollients, ultraviolet absorbers, preservatives, bactericides, emulsifiers, antioxidants, pH adjusting agents, organic and inorganic pigments, And may further contain additives commonly used in the art.
  • the amount of the additional ingredient such as the preservative may be easily selected by a person skilled in the art within the range not impairing the object and effect of the present invention, and the amount thereof may be 0.001 to 40% by weight based on the total weight of the composition.
  • the pharmaceutical composition may contain the effective amount or the effective component of the flocululin.
  • the effective amount may be appropriately selected depending on the individual.
  • the severity of the disease, the age, body weight, health, sex, sensitivity of the patient to the drug, time of administration, route of administration and rate of release, duration of treatment, factors involved in the combination or concurrent use with the composition Can be determined according to well-known factors.
  • Administration can be by any method known in the art. Administration may be by any means directly administered to a subject, such as by intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal or subcutaneous administration, .
  • the administration can be systemically or locally administered.
  • the subject may be a mammal, such as a person, a cow, a horse, a pig, a dog, a sheep, a goat, or a cat.
  • the subject may be an individual in need of skin aesthetic improvement, for example skin moisturizing, barrier enhancement, or skin regeneration effect.
  • Such administration may comprise from 0.1 mg to 1000 mg, such as from 0.1 mg to 500 mg, from 0.1 mg to 100 mg, from 0.1 mg to 50 mg, from 0.1 mg to 25 mg, or from 0.1 mg to 100 mg per day of a composition for skin care comprising floculline , 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg Or 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg, 10 mg to 50 mg, or 10 mg to 25 mg.
  • a composition for skin care comprising floculline , 1 mg to 1,000 mg, 1 mg to 500 mg, 1 mg to 100 mg, 1 mg to 50 mg, 1 mg to 25 mg, 5 mg to 1,000 mg, 5 mg to 500 mg, 5 mg to 100 mg, 5 mg Or 50 mg, 5 mg to 25 mg, 10 mg to 1,000 mg, 10 mg to 500 mg, 10 mg to 100 mg,
  • the dose may be variously prescribed depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient, These factors can be taken into account to appropriately adjust the dosage.
  • the number of doses may be at least once per day or within the range of clinically acceptable side effects and may be administered at one or two or more doses at the site of administration and may be administered daily or every two to five days The number of days of administration can be administered from one day to 30 days at one time of treatment. If necessary, the same treatment may be repeated after the appropriate time.
  • the dosage may be the same as that of a human per kg, or the dosage may be converted into a dose in terms of a volume ratio (for example, an average value) One dose may be administered.
  • the composition When the composition is a composition for a health functional food, it can be formulated into a typical health functional food formulation known in the art.
  • the health functional food may be prepared by conventional formulations such as powders, granules, tablets, pills, capsules, suspensions, emulsions, syrups, Beverages, tea, drinks, alcoholic beverages, and vitamins, such as, for example, beverages, snacks, confectionery, pizza, ramen, other noodles, gums, jellies, ice creams,
  • a pharmaceutically acceptable carrier or additive may be used for the formulation of the health food, and any carrier or additive known to be usable in the art for the preparation of the formulation to be prepared may be used.
  • additives there can be used various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, Carbonating agents, and the like.
  • it may contain natural fruit juice, fruit juice beverage and flesh for the production of vegetable beverages.
  • These additive components can be used independently or in combination, and the proportion of the additive is not critical, but can be selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition.
  • the content of the extract of floculin in the composition for health functional foods can be suitably determined according to the intended use (prevention or improvement). Generally, it may contain 0.01 to 15% by weight of the total food, and when it is prepared as a beverage, it may contain 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 mL.
  • the present inventors have found that, in the experiment using the composition containing the flocucrin, it is possible to improve the expression of pilar green, the expression of clodin 1, the expression of hyaluronic acid synthase, the expression of exfoliating enzyme, Melanin production inhibitory effect was confirmed. Therefore, a composition containing flocucurin can be usefully used for the treatment of skin cosmetics or skin-related diseases.
  • the composition containing flocurin exhibits skin barrier improvement, moisturizing, whitening, cell proliferation effect, etc., and promotes collagen synthesis and elastin synthesis, so that it can be used for skin beauty.
  • FIG. 1 is a graph showing the effect of increasing fila green expression of flocucrin in HaCat cells.
  • FIG. 2 is a graph showing the effect of increasing the expression of claudin 1 of flocucrin in HaCat cells.
  • FIG. 3 is a graph showing the effect of increasing HAS3 expression of flocucrin in HaCat cells.
  • 5 is a graph showing the effect of inhibiting the production of melanin of flocucrin in HaCat cells.
  • Example One Floculine Ready
  • Sakaromayses Paz Astoria Augustine (Saccharomyces Pastorianus ) was cultured according to the method of Marika H. (1994, Purification and partial characterization of a flocculin from brewer's yeast), and a solution containing flocucurin was isolated.
  • the separated flocucrin solution was prepared by powder freezing at -70 ° C and 5.0 Torr.
  • Sakaromayses Waves Story Janus were cultured according to the method of Marika H. (1994.Purification and partial characterization of a flocculin from brewer's yeast).
  • the yeast culture was centrifuged at 3500 rpm, and the supernatant was filtered with a 0.45 ⁇ m membrane filtration membrane.
  • the sterilized yeast culture was lyophilized at -70 ° C and 5.0 Torr to produce powder.
  • HaCat a human keratinocyte cell line, was purchased from the American Type Culture Collection (ATCC, Rockville, Md., USA), supplemented with 10% fetal bovine serum (FBS, ATCC, Rockville, MD, USA) and 1% antibiotic / antimycotic Were incubated in DMEM (Hyclone, Logan, UT, USA) supplemented with ATCC, Rockville, MD, USA at 37 ° C and 5% CO 2 .
  • ATCC American Type Culture Collection
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • DMEM Hyclone, Logan, UT, USA
  • human keratinocytes After the cells inoculated with 5 x 10 5 cells / well density in 6-well cell culture plate, with 10% of FBS with 1% AA added medium And cultured in a 5% CO 2 incubator at 37 ° C for 24 hours. To the cultured cells, Comparative Example 1 or Example 1 was added, followed by culturing for 24 hours. Cells were recovered and RNA was isolated by adding 1 ml of trizol (RNA iso, TAKARA, Japan).
  • RT-PCR was performed using a PCR machine (Step One Plus, Applied Biosystems, USA) and CyberGreen supermix (Applied Biosystems, USA) Polymerization was carried out at 95 ° C for 30 seconds, 54 ° C for 1 minute, and 72 ° C for 1 minute for 40 cycles.
  • the nucleotide sequences of the primers are shown in Table 1 below.
  • Example 1 As a result, it was observed that the pilar green expression was improved 2.84 times in the Example 1 addition group compared to the no treatment group (Fig. 1). Thus, the skin barrier enhancement effect of the composition of Example 1 can be expected.
  • Pillar green primer sequence Name of the primer order Pillar Green Forward 5'-GGCACTGAAAGGCAAAAAGG-3 '(SEQ ID NO: 1) Reverse 5'-AAACCCGGATTCACCATAATCA-3 '(SEQ ID NO: 2) beta -actin Forward 5'-GGCCATCTCTTGCTCGAAGT-3 '(SEQ ID NO: 3) Reverse 5'-GACACCTTCAACACCCCAGC-3 '(SEQ ID NO: 4)
  • HaCat a human keratinocyte cell line, was purchased from the American Type Culture Collection (ATCC, Rockville, Md., USA), supplemented with 10% fetal bovine serum (FBS, ATCC, Rockville, MD, USA) and 1% antibiotic / antimycotic Were incubated in DMEM (Hyclone, Logan, UT, USA) supplemented with ATCC, Rockville, MD, USA at 37 ° C and 5% CO 2 .
  • ATCC American Type Culture Collection
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • DMEM Hyclone, Logan, UT, USA
  • RT-PCR was carried out using a PCR machine (Step One Plus, Applied Biosystems, USA) and CyberGreen supermix (Applied Biosystems, USA) with Claudin 1 primer and cDNA for 2 min at 50 ° C, At 95 ° C for 10 seconds and at 60 ° C for 1 minute for 40 cycles.
  • the nucleotide sequences of the primers are shown in Table 2 below.
  • the expression level of the gene was finally analyzed by correction for the ⁇ -actin gene.
  • HaCat a human keratinocyte cell line, was purchased from the American Type Culture Collection (ATCC, Rockville, Md., USA), supplemented with 10% fetal bovine serum (FBS, ATCC, Rockville, MD, USA) and 1% antibiotic / antimycotic Were incubated in DMEM (Hyclone, Logan, UT, USA) supplemented with ATCC, Rockville, MD, USA at 37 ° C and 5% CO 2 .
  • ATCC American Type Culture Collection
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • DMEM Hyclone, Logan, UT, USA
  • RT-PCR was performed using PCR machine (Step One Plus, Applied Biosystems, USA) and SYBR Green supermix (Applied Biosystems, USA) was added with HAS3 primer and cDNA to activate polymerase for 5 min at 94 ° C, 95 Deg.] C for 30 seconds, 54 [deg.] C for 1 minute, and 72 [deg.] C for 1 minute.
  • the nucleotide sequences of the primers are shown in Table 3 below.
  • the expression level of the gene was finally analyzed by correction for the ⁇ -actin gene.
  • Example 1 As a result, it was confirmed that flocoolin of lager yeast (Example 1) expressed a larger amount of hyaluronic acid synthase than the conventional yeast culture (Comparative Example 1) (Fig. 3). Therefore, since the increased hyaluronic acid synthase can enhance the water-trapping ability in the skin, excellent skin moisturizing effect of the composition of Example 1 can be expected.
  • HaCat a human keratinocyte cell line, was purchased from the American Type Culture Collection (ATCC, Rockville, Md., USA), supplemented with 10% fetal bovine serum (FBS, ATCC, Rockville, MD, USA) and 1% antibiotic / antimycotic Were incubated in DMEM (Hyclone, Logan, UT, USA) supplemented with ATCC, Rockville, MD, USA at 37 ° C and 5% CO 2 .
  • ATCC American Type Culture Collection
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • FBS fetal bovine serum
  • DMEM Hyclone, Logan, UT, USA
  • RT-PCR was performed using a PCR machine (Step One Plus, Applied Biosystems, USA) and CyGreen supermix (Applied Biosystems, USA) was added with KLK7 primer and cDNA for 2 min at 50 ° C, 10 min at 95 ° C After the reaction, polymerization was carried out at 95 ° C for 10 seconds and 40 ° C for 1 minute at 60 ° C.
  • the base sequences of the primers are shown in Table 4 below. The expression level of the gene was finally analyzed by correction for the ⁇ -actin gene.
  • Example 1 It was confirmed that flocucurin of lager yeast (Example 1) expressed a greater amount of keratolytic enzyme (KLK7) compared to the general yeast culture (Comparative Example 1) (Fig. 4). Therefore, a smooth and bright skin tone correction effect of the composition of Example 1 can be expected.
  • B16 F10 cells a murine melanoma
  • DMEM fetal bovine serum
  • FBS fetal bovine serum
  • 0.1 ⁇ M ⁇ -MSH was added, and then added for each sample, followed by culturing for 3 days.
  • arbutin was treated at 100 ppm.
  • the cultured cells were washed with PBS and trypsin.
  • the recovered cells were counted with a hematocytometer and collected at 1 ⁇ 10 6 cells / mL for each treatment group, and centrifuged at 1000 rpm for 10 minutes to obtain cells.
  • the recovered cells were dried at 60 ° C for 1 hour, and 100 ⁇ l of a 1 M NaOH solution containing 10% DMSO was added to obtain melanin in the cells. This melanin solution was assayed for absorbance at 490 nm with a microplate reader to evaluate the inhibition of melanin formation.
  • Example 1 As a result, it was confirmed that flocoolin of lager yeast (Example 1) inhibited melanin production more than the conventional yeast culture (Comparative Example 1) (FIG. 5). Thus, the composition of Example 1 can have an excellent whitening effect by inhibiting the production of melanin in skin cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cell Biology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un aspect de l'invention concerne une composition pour le soin de la peau comprenant de la floculine. La composition comprenant de la floculine présente les effets d'une amélioration de la barrière cutanée, d'hydratation, de blanchiment, de prolifération cellulaire, etc, et favorise la synthèse du collagène et la synthèse de l'élastine, lui permettant ainsi d'être utilisée pour le soin de la peau.
PCT/KR2019/000184 2018-01-12 2019-01-07 Composition pour le soin de la peau comprenant de la floculine WO2019139307A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201980000340.5A CN110267643B (zh) 2018-01-12 2019-01-07 包括絮凝蛋白的用于皮肤美容的组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180004614A KR102037039B1 (ko) 2018-01-12 2018-01-12 플록쿨린을 포함하는 피부 미용을 위한 조성물
KR10-2018-0004614 2018-01-12

Publications (1)

Publication Number Publication Date
WO2019139307A1 true WO2019139307A1 (fr) 2019-07-18

Family

ID=67219839

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/000184 WO2019139307A1 (fr) 2018-01-12 2019-01-07 Composition pour le soin de la peau comprenant de la floculine

Country Status (3)

Country Link
KR (1) KR102037039B1 (fr)
CN (1) CN110267643B (fr)
WO (1) WO2019139307A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102426686B1 (ko) * 2021-11-04 2022-08-01 (주)지에프씨생명과학 벨루가 캐비아 엑소좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100084209A (ko) * 2009-01-16 2010-07-26 서원대학교산학협력단 발효 알리티아민 추출물을 함유하는 화장료 조성물
KR20110109568A (ko) * 2010-03-31 2011-10-06 주식회사 스킨푸드 맥주 효모를 이용한 미백 화장료 조성물
KR20170074447A (ko) * 2015-12-22 2017-06-30 박민선 사카로미세스속 효모분해 추출물 및 그의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100084209A (ko) * 2009-01-16 2010-07-26 서원대학교산학협력단 발효 알리티아민 추출물을 함유하는 화장료 조성물
KR20110109568A (ko) * 2010-03-31 2011-10-06 주식회사 스킨푸드 맥주 효모를 이용한 미백 화장료 조성물
KR20170074447A (ko) * 2015-12-22 2017-06-30 박민선 사카로미세스속 효모분해 추출물 및 그의 제조방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARBULOVA, A. ET AL.: "Plant cell cultures as source of cosmetic active ingredients", COSMETICS, vol. 1, 2014, pages 94 - 104, XP002780567, doi:10.3390/cosmetics1020094 *
KWIATKOWSKI, S. ET AL.: "Yeast (Saccharomyces cerevisiae) glucan polysaccharides-occutrence, separation and application in food, feed and health industries", THE COMPLEX WORLD OF POLYSACCHARIDES, 2012, pages 47 - 70, XP055625139 *

Also Published As

Publication number Publication date
CN110267643A (zh) 2019-09-20
KR20190086280A (ko) 2019-07-22
CN110267643B (zh) 2022-12-30
KR102037039B1 (ko) 2019-10-28

Similar Documents

Publication Publication Date Title
KR102009633B1 (ko) 아스페르길루스 크리스타투스 균주로 고체발효시킨 발효 인삼의 추출물을 포함하는 피부미용 개선용 조성물
WO2019143055A1 (fr) Composition comprenant un extrait de haricots fermentés obtenu à partir d'une fermentation par une souche d'aspergillus fumigatus, pour l'amélioration de soins cutanés
TWI747280B (zh) 余甘子萃取發酵物及其製備與應用
KR101963572B1 (ko) 아스페르길루스 크리스타투스 균주로 발효시킨 발효 제비집의 추출물을 포함하는 피부미용 개선용 조성물
WO2019139307A1 (fr) Composition pour le soin de la peau comprenant de la floculine
KR102019642B1 (ko) 아스페르길루스 크리스타투스 균주로 발효시킨 발효 콩의 추출물을 포함하는 피부미용 개선용 조성물
KR102406594B1 (ko) 락토바실러스 사케이 amp 5104 균주 및 이의 용도
KR102046298B1 (ko) 아스페르길루스 크리스타투스 균주로 발효시킨 발효 표고버섯의 추출물을 포함하는 피부미용 개선용 조성물
WO2023132415A1 (fr) Composition pour la réduction des rides de la peau, l'hydratation, l'amélioration de la barrière cutanée et la régénération de la peau, comprenant une souche complexe de bactéries lactiques en tant que principe actif
KR102004150B1 (ko) 아스페르길루스 크리스타투스 균주로 발효시킨 발효 인삼의 추출물을 포함하는 피부미용 개선용 조성물
KR20200022748A (ko) 로도박터 스페로이데스 균주 또는 이의 배양액을 포함하는 노화 예방 또는 개선용 조성물
KR102495405B1 (ko) 마이크로코커스 루테우스 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102174525B1 (ko) 신규한 판토에아 왈리시 루미테리아 균주 및 그 균주 배양액을 포함하는 피부 미용 개선용 조성물
KR102273234B1 (ko) 코쿠리아 바리안스 균주 및 그의 피부 상태 개선 용도
KR20220096031A (ko) 브레비바실러스 보스테렌시스 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102495404B1 (ko) 브레분디모나스 베지큘라리스 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102495402B1 (ko) 버크홀데리아 비에트나미엔시스 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102480529B1 (ko) 큐티박테리움 그래뉼로섬 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102480527B1 (ko) 코쿠리아 팔루스트리스 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102495400B1 (ko) 노보스핑고비움 후미 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102480526B1 (ko) 다이어트지아 신나메아 균주 및 그의 모발 또는 두피 상태 개선 용도
KR102558084B1 (ko) 두피 마이크로바이옴 콤플렉스 및 그의 모발 또는 두피 상태 개선 용도
WO2022045638A1 (fr) Composition destinée à améliorer l'état de la peau contenant, en tant que principe actif, un extrait de nid de pétrel-tempête fermenté à l'aide d'une nouvelle souche du genre lactobacillus
KR20220096258A (ko) 스트렙토코커스 뉴모니아 균주 및 그의 모발 또는 두피 상태 개선 용도
KR20220096000A (ko) 골도니아 테레 균주 및 그의 모발 또는 두피 상태 개선 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19738595

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19738595

Country of ref document: EP

Kind code of ref document: A1